처방약 시장 규모, 점유율, 성장 분석 : 제품 유형별, 치료 영역별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2025-2032년)
Prescription Drugs Market Size, Share, Growth Analysis, By Product Type (Generics, Orphan), By Therapy Area (Oncology, Immunology), By Route of Administration, By End-Users, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1630672
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2025년 01월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 처방약 시장 규모는 2023년에 1조 2,257억 8,000만 달러로 평가되며, 2024년 1조 3,348억 7,000만 달러에서 2032년에는 2조 6,403억 6,000만 달러로 성장하며, 예측 기간 중(2025-2032년) CAGR은 8.9%로 성장할 전망입니다.
OTC(over-the-counter) 치료는 처방약보다 약효가 약하고, 오남용시 부작용이 발생할 수 있습니다. 따라서 이러한 의약품은 의사의 처방전을 통해만 구할 수 있으며, 처방전 패드나 약국 간판에 'Rx'라고 표시되어 있는 경우가 많습니다. 전 세계 의약품 지출은 예측 기간 중 상당한 시장 성장을 촉진할 것으로 예상되며, 그 주요 이유는 특수 의약품의 비용 증가와 만성질환 및 희귀질환의 치료 증가에 기인합니다. 이러한 추세는 특히 북미에서 큰 시장 점유율을 차지하고 있는 고령화로 인해 더욱 복잡해지고 있으며, 아시아태평양은 의료를 필요로 하는 방대한 인구를 바탕으로 빠르게 성장하고 있습니다. 헬스케어 인프라 투자 강화는 시장 기회를 더욱 확대할 것으로 보입니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요의 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
기술의 진보
규제 상황
사례 연구
처방약 시장 규모 : 제품 유형별
시장 개요
제네릭
Orphan
기타 처방약
처방약 시장 규모 : 치료 영역별
시장 개요
종양학
면역학
안과
호흡기
피부과
소화기 내과
비뇨기과
부인과
내분비학
기타
처방약 시장 규모 : 투여 경로별
시장 개요
경구
국소
비경구
기타
처방약 시장 규모 : 최종사용자별
시장 개요
병원
전문 클리닉
홈케어
기타
처방약 시장 규모 : 유통 채널별
시장 개요
병원 약국
소매 약국
온라인 약국
기타
처방약 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
회사 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출의 전년대비 비교(2022-2024)
주요 기업 개요
Pfizer Inc.(United States)
Johnson & Johnson(United States)
Roche Holding AG(Switzerland)
Merck & Co., Inc.(United States)
AbbVie Inc.(United States)
Novartis AG(Switzerland)
Bristol-Myers Squibb Company(United States)
Sanofi S.A.(France)
AstraZeneca plc(United Kingdom)
GlaxoSmithKline plc(GSK)(United Kingdom)
Eli Lilly and Company(United States)
Gilead Sciences, Inc.(United States)
Amgen Inc.(United States)
Bayer AG(Germany)
Takeda Pharmaceutical Company Limited(Japan)
Novo Nordisk A/S(Denmark)
Merck KGaA(Germany)
Biogen Inc.(United States)
Teva Pharmaceutical Industries Ltd.(Israel)
결론과 권장사항
KSA
영문 목차
영문목차
Global Prescription Drugs Market size was valued at USD 1225.78 billion in 2023 and is poised to grow from USD 1334.87 billion in 2024 to USD 2640.36 billion by 2032, growing at a CAGR of 8.9% during the forecast period (2025-2032).
The over-the-counter (OTC) treatments are less potent than prescription medications, leading to potential adverse effects if misused. Consequently, these medications can only be obtained through a doctor's prescription, often denoted by "Rx" on prescription pads and pharmacy signage. Global pharmaceutical spending is anticipated to drive significant market growth during the forecast period, primarily due to the increasing costs of specialized drugs and the rise in medical treatments for chronic and rare illnesses. This trend is compounded by an aging population, particularly in North America, which holds a substantial market share, while the Asia-Pacific region experiences rapid growth due to its vast population in need of care. Enhanced healthcare infrastructure investments further bolster market opportunities.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Prescription Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Prescription Drugs Market Segmental Analysis
Global Prescription Drugs Market is segmented by Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel and region. Based on Product Type, the market is segmented into Generics, Orphan and Other Prescription Drugs. Based on Therapy Area, the market is segmented into Oncology, Immunology, Ophthalmology, Respiratory, Dermatology, Gastroenterology, Urology, Gynaecology, Endocrinology and Others. Based on Route of Administration, the market is segmented into Oral, Topical, Parenteral and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Prescription Drugs Market
The global prescription drugs market is being significantly driven by the increasing introduction of novel products, particularly generic versions of essential medications in developed countries like the United States. These generic options are gaining traction because they often offer comparable efficacy to brand-name drugs at a fraction of the cost, making them more accessible for patients. This affordability plays a crucial role, especially for individuals who cannot afford high-priced medications, as well as those in emerging markets facing financial constraints. Such trends underscore the potential for enhanced clinical outcomes and are projected to propel market growth throughout the forecast period.
Restraints in the Global Prescription Drugs Market
The global prescription drugs market is facing significant restraints that impede its growth, primarily due to the high costs associated with many medications. As essential health issues like cancer and cardiovascular diseases rise, particularly in developing regions such as Africa, Latin America, and Asia, the affordability of new products remains a critical barrier. These exorbitant prices, often ranging from USD 100,000 to USD 500,000, limit access to treatment for a substantial number of patients, many of whom encounter financial strain as they seek these essential drugs. Consequently, the lack of widespread adoption of effective medications poses a challenge for market expansion.
Market Trends of the Global Prescription Drugs Market
The Global Prescription Drugs market is witnessing a significant trend characterized by heightened R&D investments from leading pharmaceutical companies aimed at developing innovative drugs. This surge is largely driven by the rising prevalence of chronic diseases worldwide, leading to increased patient demand for effective treatments to address unmet clinical needs. As these chronic disorders often require aggressive treatment strategies, pharmaceutical firms are intensifying their efforts in clinical trials to bring new therapies to market. Additionally, there is a notable shift towards developing medications for rare diseases, which further propels market growth as companies aim to fulfill niche yet critical healthcare needs.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Case Studies
Global Prescription Drugs Market Size by Product Type & CAGR (2025-2032)
Market Overview
Generics
Orphan
Other Prescription Drugs
Global Prescription Drugs Market Size by Therapy Area & CAGR (2025-2032)
Market Overview
Oncology
Immunology
Ophthalmology
Respiratory
Dermatology
Gastroenterology
Urology
Gynaecology
Endocrinology
Others
Global Prescription Drugs Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Oral
Topical
Parenteral
Others
Global Prescription Drugs Market Size by End-Users & CAGR (2025-2032)
Market Overview
Hospitals
Specialty Clinics
Homecare
Others
Global Prescription Drugs Market Size by Distribution Channel & CAGR (2025-2032)
Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Global Prescription Drugs Market Size & CAGR (2025-2032)
North America (Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel)
US
Canada
Europe (Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Product Type, Therapy Area, Route of Administration, End-Users, Distribution Channel)
